Search / 123 results found

from
to
  • Updated

HOUSTON, Texas and VANCOUVER, Canada, April 10, 2021 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA" or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today presented new preclinical data on ESSA's lead product candidate, EPI-7386, at the 2021 American Association of Cancer Research (AACR) Annual Meeting, which is taking place virtually April 10-15, 2021. EPI-7386 is an investigational, highly selective, oral, small molecule inhibitor of the N-terminal domain of the androgen receptor, which exhibits high potency, low metabolism and on-target specificity.

  • Updated

HOUSTON, Texas and VANCOUVER, Canada, April 10, 2021 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA" or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today presented new preclinical data on ESSA's lead product candidate, EPI-7386, at the 2021 American Association of Cancer Research (AACR) Annual Meeting, which is taking place virtually April 10-15, 2021. EPI-7386 is an investigational, highly selective, oral, small molecule inhibitor of the N-terminal domain of the androgen receptor, which exhibits high potency, low metabolism and on-target specificity.

  • Updated

HOUSTON, April 6, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced the engagement of IQVIA Biotech, a contract research organization (CRO) to manage the Company's effort to begin potential clinical trials of WP1122 for the treatment of COVID-19.

  • Updated

IRVING, Texas, April 6, 2021 /PRNewswire/ -- Caris Life Sciences®, a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine, announced today that the Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (Pascale Foundation) has joined Caris' Precision Oncology Alliance™ (POA). The POA is a collaborative network of leading cancer centers that work together to advance comprehensive cancer profiling and establish standards of care for molecular testing in oncology through research focused on predictive and prognostic markers that improve the clinical outcomes of patients with cancer.